Alpha 2.0
Login Register
» Articles » PMID: 32135114

Ethnicity-based Differences in Breast Cancer Features and Responsiveness to CDK4/6 Inhibitors Combined with Endocrine Therapy

Overview
Journal Lancet Oncol
Specialty Oncology
Date 2020 Mar 6
PMID 32135114
Citations 7
Authors
Laura Pala
Fabio Conforti
Aron Goldhirsch
Affiliations
Soon will be listed here.
Citing Articles

Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?.

Gianni C, Nicolo E, Cristofanilli M Transl Breast Cancer Res. 2024; 5:34.

PMID: 39534583 PMC: 11557154. DOI: 10.21037/tbcr-24-41.

Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers.

Lee J, Lee J, Chung M, Choi J, Sim S, Kim H BMC Med. 2024; 22(1):422.

PMID: 39334392 PMC: 11438198. DOI: 10.1186/s12916-024-03638-y.

Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.

OSullivan C, Clarke R, Goetz M, Robertson J JAMA Oncol. 2023; 9(9):1273-1282.

PMID: 37382948 PMC: 11385778. DOI: 10.1001/jamaoncol.2023.2000.

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.

Masuda N, Chen Y, Kawaguchi T, Dozono K, Toi M Cancer Manag Res. 2022; 14:1179-1194.

PMID: 35342308 PMC: 8943964. DOI: 10.2147/CMAR.S348591.

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt J, Kawaguchi T Breast Cancer. 2021; 29(1):174-184.

PMID: 34661821 PMC: 8732856. DOI: 10.1007/s12282-021-01295-0.